3-Year Comparison of Drug-Eluting Versus Bare-Metal Stents  by Applegate, Robert J. et al.
3
B
R
M
S
W
O
a
c
B
s
M
1
F
b
R
r
d
1
w
c
2
C
c
l
e
F
F
s
M
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S V O L . 2 , N O . 3 , 2 0 0 9
© 2 0 0 9 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N I S S N 1 9 3 6 - 8 7 9 8 / 0 9 / $ 3 6 . 0 0
P U B L I S H E D B Y E L S E V I E R I N C . D O I : 1 0 . 1 0 1 6 / j . j c i n . 2 0 0 8 . 1 2 . 0 1 0-Year Comparison of Drug-Eluting Versus
are-Metal Stents
obert J. Applegate, MD, FACC, Matthew T. Sacrinty, MPH,
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inston-Salem, North Carolina
bjectives The aim of this study was to compare 3-year cumulative outcomes to landmark second-
nd third-year outcomes with the routine use of drug-eluting stents (DES) (75% “off-label”) with a
omparable group treated with bare-metal stents (BMS).
ackground Long-term safety concerns after “off-label” DES use persist, despite recent 2-year data
howing comparable safety to BMS use.
ethods Clinical outcomes (nonfatal myocardial infarction, all-cause mortality) were assessed in
,147 consecutive patients who received a BMS in the year before the introduction of DES at Wake
orest University Baptist Medical Center and 1,246 consecutive patients that received a DES after it
ecame our routine choice with equivalent complete 3-year follow-up.
esults Stents were used for “off-label” indications in 80% of DES patients. At 3 years, the hazard
atio for DES compared with BMS for cumulative target vessel revascularization was 0.65 (95% conﬁ-
ence interval [CI]: 0.51 to 0.82), nonfatal myocardial infarction or death was 0.85 (95% CI: 0.71 to
.03), and all-cause mortality 0.80 (95% CI: 0.64 to 1.01). The DES clinical beneﬁts occurred entirely
ithin the ﬁrst year, with similar rates of these clinical end points in the second and third year. The
umulative hazard ratio of stent thrombosis DES compared with BMS was 1.07 (95% CI: 0.57 to
.01), with similar rates of stent thrombosis in the third year (p  0.70).
onclusions The routine clinical use of DES for “off-label” indications was associated with lower
linical end points at 3 years than treatment with BMS in a comparable group of patients, with simi-
ar cumulative rates of stent thrombosis. There was no evidence of late “catch-up” of adverse DES
vents. (J Am Coll Cardiol Intv 2009;2:231–9) © 2009 by the American College of Cardiology
oundation
rom Wake Forest University School of Medicine, Section of Cardiology, Winston-Salem, North Carolina. This work was
upported in part by a grant from Cordis Corporation.anuscript received October 15, 2008; revised manuscript received November 24, 2008, accepted December 11, 2008.
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PCI percutaneous coronary intervention.
A
a
B
C
D
H
M
P
c
S
T
r
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 3 , 2 0 0 9
M A R C H 2 0 0 9 : 2 3 1 – 9
Applegate et al.
Three-Year Comparison of DES vs. BMS
232oncerns of stent thrombosis (ST) more than 1 year after
lacement of drug-eluting stents (DES) (1–3) have fueled an
xtensive evaluation of the late safety of these devices (4,5),
articularly in higher-risk patients receiving DES for “off-
abel” indications (6,7). Importantly, some studies have ob-
erved a rate of late ST of up to 0.6%/year for several years after
ES, without evidence of reduction in the incidence of this
ow frequency event (8). Whereas attention has been focused
n late ST, several recent single-center and registry studies
ave observed that hard cardiac end points including nonfatal
yocardial infarction (MI) and death are lower after the use of
ES compared with bare-metal stents (BMS) in routine
ractice at 1 to 2 years after stent treatment (9–11). Whether
he beneficial outcomes observed with DES compared with
MS persist after 2 years remains uncertain. Accordingly, we
ompared clinical outcomes, including rates of ST, nonfatal
I, and death at 3 years, in well-matched groups of patients
reated with DES and BMS in routine clinical practice,
ncluding a large majority of high-risk patients treated for
off-label” indications.
Methods
Patients at our institution under-
going percutaneous coronary in-
tervention (PCI) from April 2002
to April 2005 were included in the
study. Consecutive patients (n 
1,164) representing all patients
who underwent coronary artery
stenting between April 2002 and
April 2003, before the Food and
Drug Administration approval of
DES in the United States, re-
eived BMS and served as the control group. The study group
onsisted of 1,285 consecutive patients who received DES after
hese stents were fully available (February 2004) and had
eplaced BMS as our routine stents of choice (90% use). Any
atient that had a BMS placed after the availability of DES
as excluded from this study to minimize selection bias of stent
ype when both BMS and DES were available. Patients were
lso excluded if they received both BMS and DES (n  8) or
ere unavailable for follow-up (BMS  17; DES  31).
atients were not excluded from the study for any other reason.
hus, 1,147 BMS and 1,246 DES patients comprised the
ontrol and study groups, respectively. The study was approved
y the Institutional Review Board of Wake Forest University
aptist Medical Center. We have previously reported the
-month (12) and 2-year (9) follow-up of most of these
atients.
PCI was performed according to standard techniques. Be-
ause sirolimus-eluting stents were available much earlier than
aclitaxel-eluting stents, they comprised most of the DES used
bbreviations
nd Acronyms
MS  bare-metal stent(s)
I  confidence interval
ES  drug-eluting stent(s)
R  hazard ratio
I  myocardial infarction
CI  percutaneous
oronary intervention
T  stent thrombosis
VR  target vessel
evascularizationn the study: sirolimus-eluting stents  972; paclitaxel-elutingTable 1. Baseline Clinical and Procedural Characteristics by Stent Type
Characteristic BMS (n  1,147) DES (n  1,246) p Value
Male gender 66% 65% 0.600
Age, yrs 64 12 63 12 0.165
Heart failure class III or IV 15% 16% 0.533
Current smoker 31% 34% 0.149
Diabetes mellitus 32% 32% 0.638
Hypertension 76% 78% 0.309
Hypercholesterolemia 68% 65% 0.210
Vascular disease 20% 18% 0.224
History of renal failure 5% 6% 0.222
Previous PCI 29% 23% 0.003
Previous CABG 17% 16% 0.491
Left ventricular ejection
fraction, %
48 16 50 11 0.247
Indications for procedure
Myocardial infarction
within 7 days
37% 41% 0.083
On-label 25% 20% 0.004
Off-label 75% 80% 0.004
Target lesion vessel
Native coronary artery 93% 94% 0.304
Saphenous vein graft 7% 6% 0.341
Procedural
Number of vessels
stented
1.2 0.4 1.2 0.4 0.173
Number of lesions
stented
1.5 0.8 1.4 0.7 0.629
Stented length per
lesion, mm
20 10 25 8 0.001
BMS bare-metal stent(s); CABG coronary artery bypass grafting; DES drug-eluting stent(s);Table 2. Post-Index Procedure Medications Use by Stent Type
Medication BMS DES p Value
Clopidogrel
At 6 months 388/693 (56) 784/1,057 (74) 0.001
At 1 yr 340/686 (50) 601/1,051 (57) 0.002
At 2 yrs 297/678 (44) 494/1,043 (47) 0.148
At 3 yrs 263/669 (39) 378/1,024 (37) 0.320
Aspirin
At 6 months 625/647 (97) 980/1,004 (98) 0.224
At 1 yr 611/640 (95) 968/998 (97) 0.106
At 2 yrs 594/632 (94) 951/990 (96) 0.056
At 3 yrs 578/623 (93) 877/980 (90) 0.027
Statin
At 6 months 594/687 (86) 931/1,053 (88) 0.227
At 1 yr 593/680 (87) 931/1,047 (89) 0.280
At 2 yrs 574/672 (85) 941/1,039 (91) 0.001
At 3 yrs 566/663 (85) 801/1,020 (79) 0.001
Each time interval expressed as No. using / No. alive (%). Medications data were not available for
all patients.Abbreviations as in Table 1.
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233tents  262; both  12. Anticoagulation during PCI was
ccomplished with unfractionated heparin or bivalirudin per
tandard protocol. Patients received glycoprotein IIb/IIIa re-
eptor inhibition according to usual protocol with abciximab or
ptifibatide at the discretion of the interventionalist (12). All
atients were treated with aspirin (81 to 325 mg/day) before
CI and indefinitely thereafter. Patients also received clopi-
ogrel (300 to 600 mg as a loading dose, given before or
mmediately after the procedure, followed by 75 mg/day).
lopidogrel was given for a minimum of 1 month in BMS-
reated patients, for a minimum of 3 months for sirolimus-
luting stent-treated patients, and for a minimum of 6 months
or paclitaxel-eluting stent-treated patients. Additional clopi-
ogrel use was at the discretion of the physician responsible for
linical care of the patient.
Before hospital discharge, patient and procedural data and
ospital outcomes were entered into the Wake Forest Univer-
ity Baptist Medical Center Cardiovascular Information Ser-
Figure 1. Kaplan-Meier Plots of Cumulative Incidence and Landmark Incide
BMS  bare-metal stent(s); DES  drug-eluting stent(s); HR  hazard ratio.ices Database. Collection of data and outcomes measures tonformed to the American College of Cardiology National
ardiovascular Database Registry definitions for cardiovascular
ata (13). Clinical follow-up was obtained as follows: indepen-
ent chart review, including a follow-up visit with a cardiolo-
ist at 3 years, was available for 80% of patients; and review of
he Social Security Death Index for which the death records
ere the only available follow-up in 2% of patients. Scripted
hone interviews at 3 years were obtained in 18% of patients
ho did not have follow-up with either chart or Social Security
eath Index review. Events occurring at outside institutions
ere reviewed and confirmed. Follow-up was censored at 3
ears  30 days, with complete 3-year follow-up available in
6% of BMS and 91% of DES patients. All patients reported
n the study had clinical follow-up. In the patients in whom
omplete 3-year follow-up was not available, outcomes were
ncluded in all Kaplan-Meier and Cox proportional hazards
nalysis until the point they were lost to follow-up.
Stent thrombosis was defined following the recommenda-
f Target Vessel Revascularizationnce oions of the Academic Research Consortium (ARC) for
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234efinite and probable ST as presentation with acute coronary
yndrome (ACS) and definite angiographic or pathologic
vidence of ST, unexplained death within 30 days of stent
lacement, or target vessel infarction in the absence of angiog-
aphy (14). “On-label” stent use was patterned after the study
riteria used in the initial randomized DES studies (15,16), as
ollows: 18 years old; single de-novo native coronary artery
esions 30 mm in length without thrombus; left ventricular
jection fraction25%; no MI within 7 days of the procedure;
nd no evidence of renal failure (serum creatinine2.0 mg/dl).
tent use in all other patients was defined as “off-label.” This
efinition of “on-label” use is similar to the information for use
uidelines for both Cypher (Cordis Corporation, Miami,
lorida) and TAXUS (Boston Scientific, Inc., Billerica, Mas-
achusetts) with the exception that renal failure was not
pecifically listed as a contraindication for DES use in the
nstructions for use. Nonfatal MI was defined as ischemic
Figure 2. Kaplan-Meier Plots of Cumulative Incidence and Landmark Incide
Abbreviations as in Figure 1.ymptoms and an elevation of creatine kinase-myocardial band t2 the upper limit of normal, with or without ST-segment
levation or development of Q waves. Periprocedural MIs
rising at the time of the index procedure were not included in
he outcomes.
tatistical methods. Descriptive statistics (means and SD of
ontinuous factors, frequency counts and relative frequencies of
ategorical factors) were calculated and compared with the
ilcoxon rank sum test for continuous factors and chi-square
esting for categorical factors. Hazard ratios (HRs) are pre-
ented along with their 95% confidence intervals (CIs).
aplan-Meier plots of cumulative incidence were constructed
rom index procedure to 3 years of follow-up. The log-rank test
as used to test for differences between DES and BMS
ncidence curves. Cox proportional hazards modeling was used
o assess independent predictors of outcomes at 3 years to
ccount for follow-up data censored before 3 years. All mea-
ured baseline patient and procedural variables were included in
f Stent Thrombosisnce ohe model regardless of clinical significance and removed in a
b
s
K
P
o
t
i
p
e
m
S
C
R
T
g
a
p
o
d
p
b
i
0
t
D
i
o
f
g
f
a
r
J A C C : C A R D I O V A S C U L A R I N T E R V E N T I O N S , V O L . 2 , N O . 3 , 2 0 0 9
M A R C H 2 0 0 9 : 2 3 1 – 9
Applegate et al.
Three-Year Comparison of DES vs. BMS
235ackward stepwise fashion until all remaining covariates were
tatistically significant predictors of outcome (p  0.05).
nown clinical predictors of outcome (i.e., MI indication for
CI, heart failure, age) were retained in the models regardless
f statistical significance. Because of the low rates of stent
hromboses, we dropped all nonstatistically significant variables
ncluding clinical predictors from the multivariate model. The
roportional hazards assumption was tested for all variables by
xamining log-log survival curves. No variables in the final
odels violated the proportional hazards assumption. The
AS, Version 9.1 Statistical Software Package (SAS Institute,
ary, North Carolina) was used for all statistical analyses.
esults
he baseline clinical characteristics of the BMS and DES
roups were similar (Table 1). By study criteria 75% of BMS
Figure 3. Kaplan-Meier Plots of Cumulative Incidence and Landmark Incide
MI  myocardial infarction; other abbreviations as in Figure 1.nd 80% of DES (p 0.004), were “off-label” patients and/or Brocedures, including treatment for MI within 7 days in 37%
f BMS and 41% of DES patients (p 0.08). Medication use
uring the follow-up period was available for most of the
atients in the study (Table 2). Aspirin use remained90% in
oth groups at 3 years. Clopidogrel use was higher at 6 months
n the DES group (74%) versus the BMS group (56%) (p 
.002). Thereafter, clopidogrel use declined and was essentially
he same. At 3 years, clopidogrel use was 39% BMS and 37%
ES (p 0.29). At 3 years, any antiplatelet therapy was in use
n 95% of BMS and 91% of DES (p  0.006).
Kaplan-Meier plots of the cumulative incidence of selected
utcomes at 3 years as well as for each year during the
ollow-up period are shown for the entire BMS and DES
roups in Figures 1 to 4. The clinical and procedural covariates
or each of the stent types were similar for each time period
nalyzed (p  0.05). The cumulative hazard of target vessel
evascularization (TVR) was lower with DES compared with
f Nonfatal MI or Deathnce oMS (HR: 0.65, 95% CI: 0.51 to 0.82). The DES TVR
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236enefit occurred entirely within the first year, with similar rates
f TVR in the second and third year. The 3-year cumulative
azard of ST was 1.07 (95% CI: 0.57 to 2.01). There was no
MS ST during the second year, but there were 7 DES stent
hromboses. There were 2 stent thromboses during the third
ear in the BMS group and 3 in the DES groups (p  0.99).
here was a lower cumulative hazard of death in the DES
roup compared with the BMS group that persisted out to 3
ears (HR: 0.80, 95% CI: 0.64 to 1.01). The cumulative hazard
f nonfatal MI or death was also lower in the DES patients
ompared with the BMS patients (HR: 0.85, 95% CI: 0.71 to
.03). The DES benefit seemed to occur entirely within the
rst year, with similar rates of nonfatal MI or death in the
econd and third years.
We examined the relation between clopidogrel use and
utcomes in the first year. The overall HR for nonfatal MI or
eath was 0.62 (95% CI: 0.43 to 0.88) for those taking
lopidogrel versus those not taking clopidogrel at 6 months. In
Figure 4. Kaplan-Meier Plots of Cumulative Incidence and Landmark Incide
Abbreviations as in Figure 1.hose taking clopidogrel at the time of an event or at 6 months, ehe HR for nonfatal MI or death for DES versus BMS was
.58 (95% CI: 0.34 to 0.99). For those not taking clopidogrel
t the time of an event or at 6 months, the HR for nonfatal MI
r death for DES versus BMS was 0.76 (95% CI: 0.46 to
.25).
Multivariate analysis of ST and nonfatal MI or death for
he entire study population over the 3-year study period is
hown in Table 3. History of renal failure (HR: 2.49, 95%
I: 1.88 to 3.30), and diabetes mellitus (HR: 1.65, 95% CI:
.35 to 2.02), were 2 of the strongest independent predictors
f increased nonfatal MI or death, whereas DES use (HR:
.81, 95% CI: 0.67 to 0.99), was the strongest independent
redictor of lower nonfatal MI or death. The HRs of
onfatal MI or death for DES versus BMS were also
ompared across covariate strata (Fig. 5). For almost all of
he clinical and lesion variables assessed, the point estimate
f the HR for nonfatal MI or death favored DES, although
he upper boundaries of the 95% CIs crossed the line of
f Deathnce oquivalency.
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237iscussion
n this large, contemporary experience comprising mainly
oronary stent procedures classified as “off-label” (4,5), we
bserved comparable clinical outcomes in the third year after
tent therapy, including ST, nonfatal MI or death, and
ll-cause mortality. As a consequence, at 3 years “off-label”
ES use was associated with significantly lower cumulative
linical event rates of TVR and favorable trends in nonfatal
I or death compared with BMS use. Thus, the substantial
enefit of DES use compared with BMS use in the first year
fter stent placement was preserved, without evidence of
ignificant “catch-up” of late adverse clinical events after
ES use.
Widespread “off-label” DES use has been criticized, because
f fear of a higher incidence of late adverse events including ST
han would be observed with “on-label” DES use (17). How-
ver, several recent single-center and registry studies of “off-
abel” procedures and patients have observed similar (18) and,
n several instances, better cumulative clinical outcomes with
ES use than with BMS at 2 years (9–11). Unfortunately,
iven the substantial benefit observed in the first year after
ES use compared with BMS use and the low rate of late
ES thrombosis, the effect of late catch-up with DES might
ot be discernible at 2 years. Only limited data are available for
off-label” DES use after 3 years. Daemen et al. (8,19) have
valuated clinical event rates at 3 and 4 years in consecutive
atients treated with DES. They found comparable cumulative
Table 3. Cox Proportional Hazards Multivariate Analysis of Nonfatal MI
or Death, and Stent Thrombosis to 3 Years
Multivariate Model
Nonfatal MI or Death Stent Thrombosis
HR (95% CI) p Value HR (95% CI) p Value
Clinical variables
History of renal
failure
2.49 (1.88–3.30) 0.001
Vascular disease 1.69 (1.37–2.09) 0.001
Diabetes mellitus 1.65 (1.35–2.02) 0.001 2.05 (1.09–3.85) 0.026
MI indication for
index PCI
1.59 (1.30–1.94) 0.001 1.89 (1.01–3.54) 0.048
Hypertension 1.56 (1.17–2.10) 0.003
Heart failure class
III or IV
1.47 (1.17–1.85) 0.001
Current smoker 1.34 (1.07–1.68) 0.011
Age, per 10 yrs 1.32 (1.19–1.45) 0.001
Procedural variables
DES use 0.81 (0.67–0.99) 0.040 1.12 (0.60–2.12) 0.721
No. of lesions
stented
1.32 (1.17–1.48) 0.001 1.87 (1.40–2.50) 0.001
Only drug-eluting stent (DES) use, number of lesions stented, myocardial infarction (MI), indica-
tion for index percutaneous coronary intervention (PCI), and diabetes mellitus were included in
stent thrombosis model due to the low number of overall events.
CI confidence interval; HR hazard ratio.ates of nonfatal MI and death with DES and BMS but ceasurable rates of ST with DES and not BMS. These
bservations represent the earliest experience of DES use
utside of randomized clinical trials and, as such, might not
epresent the fullest application of DES that has been observed
ith maturation of the stent therapy, including more pro-
onged antiplatelet therapy.
The evaluation of late events after DES use in patients with
n initial uncomplicated post-stent therapy course provided the
rst clinical evidence of a possible “catch-up” with DES that
as not thought to occur with BMS, due almost exclusively to
T (1–3). Closer evaluation of 2 of the principal studies that
rought these observations to attention, BASKET-LATE
Basel Stent Cost-Effectiveness Trial: Late thrombotic. events)
nd SCAARS (Swedish Coronary Angiography and Angio-
lasty Registry) (1,2), revealed that cumulative event rates of
ES and BMS were actually similar, despite the occurrence of
ate DES thrombosis. The use of these landmark analyses
rovides evidence of low-frequency signals that might be
bscured by evaluation of cumulative outcomes only. However,
mphasis on these low-frequency events without understand-
ng their impact on cumulative end points might lead to an
nappropriate assessment of the potential benefit of stent
herapy. Moreover, as our observations suggest, rates of late
dverse clinical events due to underlying atherosclerotic coro-
ary artery disease occurs at a much greater frequency (i.e.,
%/year) than the rates due to ST (i.e., 0.5%/year).
The importance of antiplatelet therapy after stent therapy,
articularly DES use, has received increasing recognition
1,17,20,21). Although current guidelines recommend at least
year of dual antiplatelet therapy after DES (17), the optimal
uration of dual antiplatelet therapy remains uncertain. More-
ver, eliminating or significantly reducing rates of late DES
hrombosis with prolonged (1 year) dual antiplatelet therapy
emains untested (20). In this study, close to one-half of the
atients were taking clopidogrel at 2 years in addition to aspirin
approximately 95% use). Whether the use of dual antiplatelet
herapy at 3 years in this study was responsible for the apparent
ower rates of ST observed in this study compared with
ASKET-LATE (1), where clopidogrel was stopped at 6
onths by protocol, remains uncertain. Interestingly, we ob-
erved a small but significant decrease in the use of aspirin and
lopidogrel in DES patients between the second and third
ears after stent placement but with identical rates of late ST,
.5%/year. Defining the optimal duration of dual antiplatelet
fter DES use awaits the results of adequately powered
andomized clinical trials.
The potential mechanisms responsible for the lower event
ates in the DES patients were not specifically addressed in this
tudy. Greater use of clopidogrel in the DES patients com-
ared with the BMS patients at 6 months might have
ontributed to this apparent benefit of DES. Our findings
uggest that clopidogrel use likely contributed to a lower rate of
onfatal MI or death in DES patients at 6 months, because
lopidogrel use was associated with lower event rates at 6
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238onths and was more commonly used in DES than BMS
atients during the first year. However, our data also suggest
hat there were additional factors contributing to the lower rate
f nonfatal MI or death in DES patients at 6 months,
ndependent of clopidogrel use, because event rates were lower
n the first year for DES than BMS in those taking clopidogrel.
urther evaluation of potential mechanisms of DES benefit,
uch as lowering the rate of MIs associated with BMS
estenosis (22,23), needs to be performed to determine a better
nderstanding of DES effects.
Observational studies such as ours might be subject to
scertainment bias due to unequal follow-up. However, we
btained nearly complete follow-up in both groups, so that
Figure 5. Hazard Ratio Plot of Nonfatal MI or Death up to 3 Years Compari
The size of each box is proportional to the relative sample size of each strata
†8 patients did not have history of renal failure data available; ‡7 patients did
BMS  bare-metal stent(s); CHF  congestive heart failure; CI  conﬁdence in90% of the patients had follow-up available at 3 years. The mandmark analysis used in this study might result in imbalances
n baseline covariates in subsequent time periods. We evaluated
he baseline covariates of the 2 stent types for each landmark
eriod and did not observe any statistically significant differ-
nces between the 2 groups. Our study might also be con-
ounded by selection bias. However, our DES and BMS
atients had very similar baseline clinical and lesion character-
stics. Moreover, use of a recent historical control group avoids
he potential selection bias of stent therapies when both BMS
nd DES are available. Randomized clinical trials would
rovide the fairest evaluation of DES efficacy and safety, but
andomized clinical trials usually exclude the very type of
igh-risk patients that are of interest (24). Although there were
S With BMS, Stratified by Covariate
ber of patients that did not have censored follow-up data prior to 3 years;
ave diabetes mellitus data available. ACS  acute coronary syndrome;
; DES  drug-eluting stent(s); MI  myocardial infarction.ng DE
. *Num
not hore than 1,000 patients in each treatment group, the study
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239as underpowered to evaluate differences in the incidence of
T. Finally, our study did not examine outcomes beyond 3
ears. Hopefully, longer-term follow-up of cohorts such as this
ill provide valuable information concerning the relative inci-
ence of late adverse events after DES treatment.
onclusions
e observed lower cumulative rates of nonfatal MI and
ll-cause mortality at 3 years in mainly “off-label” DES-treated
atients compared with comparable BMS-treated patients.
he clinical benefits of lower rates of TVR, all-cause death,
nd nonfatal MI or all-cause death with DES compared with
MS arose entirely within the first year after stent placement.
ates of these clinical events were similar between the 2 stent
roups in the second and third year after stent placement. Left
runcation in landmark survival analysis can result in covariate
mbalances in subsequent landmark cohorts that can lead to
ias in cumulative incidence measurements of 2 separate
reatment groups, and thus landmark results should be inter-
reted within the context of overall cumulative incidence rates.
ate ST (1 year) occurred more frequently with DES than
MS in the second and third year after stent placement, but
he 3-year cumulative rates of ST were almost identical. Thus,
t 3 years, DES use in “off-label” patients seemed to retain
etter efficacy and comparable safety to that of BMS use,
ithout evidence of significant late “catch-up” due to adverse
ES events.
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